State of Wisconsin Investment Board Raises Holdings in Kite Pharma Inc (KITE)

State of Wisconsin Investment Board grew its position in Kite Pharma Inc (NASDAQ:KITE) by 151.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 90,499 shares of the biopharmaceutical company’s stock after buying an additional 54,499 shares during the quarter. State of Wisconsin Investment Board owned 0.16% of Kite Pharma worth $16,273,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the business. Stevens Capital Management LP purchased a new stake in shares of Kite Pharma in the 3rd quarter worth $9,846,000. Chicago Equity Partners LLC purchased a new stake in shares of Kite Pharma in the 3rd quarter worth $1,361,000. State Board of Administration of Florida Retirement System lifted its holdings in shares of Kite Pharma by 12.4% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 27,107 shares of the biopharmaceutical company’s stock worth $4,874,000 after buying an additional 2,980 shares during the period. Dupont Capital Management Corp lifted its holdings in shares of Kite Pharma by 95.0% in the 3rd quarter. Dupont Capital Management Corp now owns 14,600 shares of the biopharmaceutical company’s stock worth $2,625,000 after buying an additional 7,113 shares during the period. Finally, Pillar Pacific Capital Management LLC purchased a new stake in shares of Kite Pharma in the 3rd quarter worth $310,000. Institutional investors and hedge funds own 87.72% of the company’s stock.

WARNING: “State of Wisconsin Investment Board Raises Holdings in Kite Pharma Inc (KITE)” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this article can be accessed at https://ledgergazette.com/2017/11/13/state-of-wisconsin-investment-board-raises-holdings-in-kite-pharma-inc-kite.html.

Shares of Kite Pharma Inc (KITE) opened at $179.79 on Monday. Kite Pharma Inc has a one year low of $39.82 and a one year high of $179.99.

Several equities research analysts have weighed in on the company. SunTrust Banks, Inc. cut Kite Pharma from a “buy” rating to a “hold” rating in a report on Monday, August 28th. Wedbush upgraded Kite Pharma from an “underperform” rating to a “neutral” rating in a report on Tuesday, August 29th. BTIG Research cut Kite Pharma from a “buy” rating to a “neutral” rating in a report on Monday, August 28th. Jefferies Group LLC reiterated a “buy” rating and issued a $135.00 target price (up from $121.00) on shares of Kite Pharma in a report on Wednesday, August 9th. Finally, Canaccord Genuity set a $120.00 price objective on Kite Pharma and gave the stock a “buy” rating in a research note on Wednesday, August 9th. Thirteen investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $94.68.

In other Kite Pharma news, Chairman Arie Belldegrun sold 26,347 shares of the stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $179.66, for a total transaction of $4,733,502.02. Following the transaction, the chairman now owns 135,507 shares in the company, valued at $24,345,187.62. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Shawn Tomasello sold 4,203 shares of the stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $179.66, for a total value of $755,110.98. The disclosure for this sale can be found here. Insiders sold 48,936 shares of company stock worth $8,791,842 in the last 90 days. Company insiders own 14.00% of the company’s stock.

About Kite Pharma

Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.

Institutional Ownership by Quarter for Kite Pharma (NASDAQ:KITE)

Receive News & Ratings for Kite Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply